NVS vs QGEN
Novartis AG vs Qiagen N.V. — AI-powered side-by-side comparison
| Metric | NVS | QGEN |
|---|
| AI Score |
75
|
64
|
| Price |
$154.64
|
$42.66
|
| P/E Ratio |
23.55×
|
21.87×
|
| ROE |
30.5%
|
11.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
61.7%
|
| Debt / Equity |
1.18×
|
0.49×
|
| Dividend Yield |
2.9%
|
6.2%
|
| RSI (14) |
57.7
|
57.5
|
| Beta |
0.462
|
0.62
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus QGEN.
NVS leads by 11 points.
NVS scores 75/100 (Buy) versus QGEN at 64/100 (Buy).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
QGEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- EPS growing 341.4% YoY — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro